News

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

For this study, researchers focused on photoreceptor cells (PRCs), which are light-detecting cells found in the retina.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

The company’s therapeutic is a single therapy for multiple forms of age-related macular degeneration. NM3086 is a highly potent alternative pathway (AP) blocker that does not affect the classical pathway.

There are now treatments available that target VEGF to prevent vessel overgrowth, and they often provide dramatic benefits at first. Unfortunately, these benefits can fade with time.

Cedars-Sinai investigators map changes to the retina that correspond to brain changes in the early stage, opening a path to earlier diagnosis.

MCO-010 has been granted orphan drug designation by the FDA for both diseases and multiple mid- to late-stage clinical trials are ongoing.

According to the company, the award advances Praetego's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.

Researchers from Tokyo Medical and Dental University evaluated the safety of an anti-VEGF drug, aflibercept, in a cell culture model exposed to human T-cell lymphotropic virus type 1, which is known to cause a number of diseases, including inflammatory diseases of the eye.

The Keralink trial results answered an important question regarding the time at which corneal cross-linking should be performed.

Jay Chhablani, MD, provides an overview of the Subthreshold Ophthalmic Laser Society treatment guidelines for patients with diabetic macular edema.

Yusuke Oshima, MD, PhD, in a presentation at the 38th Asia-Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, discussed the advantages of using a beveled-tip ultra-speed probe for complete vitreous shaving during retinal detachment vitrectomies.

Voraporn Chaikitmongkol, MD, discussed step therapy and reported the results of a major study, the Diabetic Retinopathy Clinical Research (DRCR) Protocol AC, at the 38th Asia-Pacific Academy of Ophthalmology Congress, in Kuala Lumpur, Malaysia.

Children who ultimately develop pathologic myopia may have a different retinal appearance at an early age.

Greater anatomic improvements (central subfield thickness reduction, proportion with absence of subretinal fluid and intraretinal fluid) were seen with faricimab versus aflibercept during the matched dosing period (week 4, week 8, and week 12).

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

Apellis has received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Iveric Bio announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024

The agenda includes the Opening Ceremony, Women in Ophthalmology Luncheon, and Young Ophthalmologists’ Night, and that's only a sampling. The results of the APAO-Asia-Pacific Ocular Imaging Competition will also be announced.

Saunders is returning to Bausch + Lomb after having served at the company as CEO from 2010 to 2013.

The trial could prove to be a key development in the treatment of people with the rare inherited condition RP, which currently has no approved cure or standard treatment.

The money raised this year will help support the Princess Elizabeth National School for Special Education in Malaysia and APAO Young Ophthalmologist activities.

The family-friendly conference, being held at the El Conquistador Resort in Puerto Rico, will promote women in the field, according to founder and program director Bonnie An Henderson, MD.

If approved by the FDA later this year, phentolamine ophthalmic solution 0.75% could be the only commercially available eye drop for the reversal of dilation. It is being developed for reversal of pharmacologically-induced mydriasis, presbyopia, and dim light vision disturbances under the 505(b)(2) pathway.

The findings from a National Institutes of Health-supported clinical trial may help guide the management of diabetic eye disease.